Company intelligence / Profile preview

AmacaThera

Toronto, Ontario, Canadaamacathera.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The lead product, AMT‑143, combines an anesthetic with AmacaThera’s proprietary hydrogel to provide sustained post-surgical pain relief. Early clinical results are pending; the goal is opioid-sparing analgesia lasting up to 72 hours after surgery. The company’s technology has not previously been tested in humans and represents a novel approach to local drug depot formation and controlled release. Additional programs are preclinical or exploratory.

Therapeutic areas: OncologyNeurology
Modalities: Injectable hydrogel-based drug deliverycombination with small molecules (e.g., anesthetics)
Industry: Biotech

Drug pipeline

1 asset

AMT-143

Discontinued

Partnerships

Research Institute of St. Joseph’s Healthcare Hamilton [for health economic impact studies on non-opioid postoperative pain products].

Beyond the preview

Go deeper on AmacaThera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AmacaThera.

Explore the full profile